IBI352g4a
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human
IBI352g4a binds recombinant human PVRIG with high affinity, with a Kd of 0.53 nM[1].
IBI352g4a binds recombinant cynomolgus monkey PVRIG with a Kd of 2.71 nM[1].
IBI352g4a binds human PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 2.03 nM[1].
IBI352g4a binds cynomolgus monkey PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 7.42 nM[1].
IBI352g4a completely blocks the interaction between human PVRIG and PVRL2, with an IC50 of 0.94 nM[1].
IBI352g4a (10 μg/mL; 4 h) significantly increases degranulation (CD107a expression) in purified human NK cells cocultured with K562 cells for 4 h[1].
IBI352g4a (10 μg/mL; 16 h) significantly increases activation (CD137 expression) in purified human NK cells cocultured with K562 cells for 16 h[1].
IBI352g4a (10 μg/mL; 5 h) significantly increases NK cell-mediated killing of CTV-labeled K562 cells[1].
IBI352g4a (10 ng/mL-10 μg/mL; 4 h) induces dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:purified human NK cells, CellTrace Violet (CTV)-labeled K562 tumor cells
-
Concentration:10 μg/mL
-
Incubation Time:5 h
-
Result:Significantly increased the percentage of PI+ CTV+ dead K562 cells compared to control IgG treatment.
-
Cell Line:NK cells, K562 cells
-
Concentration:10-8, 10-6, 10-4, 10-2, 100, 102 μg/mL
-
Incubation Time:4 h
-
Result:Induced dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture.
IBI352g4a (10 mg/kg; i.p.; 6 doses on days 5-22) has limited antitumor efficacy against human gastric cancer in T-cell-only reconstituted NOG mice, indicating NK cells are critical for its optimal activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-NDG hIL15 mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 6 doses on days 7, 10, 13, 17, 20, 24
-
Result:Reduced mean tumor volume.
Maintained stable body weight throughout treatment.
-
Animal Model:NOG mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 6 doses on days 5, 8, 11, 15, 18, 22
-
Result:Showed limited antitumor efficacy, with significantly weaker activity compared to its efficacy in B-NDG hIL15 mice with NK and T cell reconstitution.
PVRIG/CD112R
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBI352g4a Related Classifications
HY-P992381 Related Classifications
Powered by Bioz